Estimated prevalence and incidence of diagnosed ADHD and health care utilization in adults in Sweden – a longitudinal population-based register study

Estimated prevalence and incidence of diagnosed ADHD and health care utilization in adults in Sweden – a longitudinal population-based register study

Maria Polyzoi,1 Ewa Ahnemark,2 Emma Medin,1,3 Ylva Ginsberg4,5 1PAREXEL International, Stockholm, Sweden; 2Medical Affairs Department, Shire Sweden AB, Stockholm, Sweden; 3Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden; 4Department of Medical Ep...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Polyzoi M, Ahnemark E, Medin E, Ginsberg Y
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
prevalence – attention-deficit/hyperactivity disorder – adult – register analysis – daily dose – methylphenidate
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Acceso en línea:https://doaj.org/article/18f9face43844ec0bb8caa0db8669008
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:18f9face43844ec0bb8caa0db8669008
record_format dspace
spelling oai:doaj.org-article:18f9face43844ec0bb8caa0db86690082021-12-02T03:02:49ZEstimated prevalence and incidence of diagnosed ADHD and health care utilization in adults in Sweden – a longitudinal population-based register study1178-2021https://doaj.org/article/18f9face43844ec0bb8caa0db86690082018-05-01T00:00:00Zhttps://www.dovepress.com/estimated-prevalence-and-incidence-of-diagnosed-adhd-and-health-care-u-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Maria Polyzoi,1 Ewa Ahnemark,2 Emma Medin,1,3 Ylva Ginsberg4,5 1PAREXEL International, Stockholm, Sweden; 2Medical Affairs Department, Shire Sweden AB, Stockholm, Sweden; 3Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden; 4Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 5Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Institutet, Stockholm, Sweden Background: Although the worldwide prevalence of attention-deficit/hyperactivity disorder (ADHD) in adults is estimated to be between 2% and 5%, it is considered to be underdiagnosed. This register study explored the prevalence of diagnosed ADHD and incidence of newly diagnosed ADHD in Swedish adults over time, and assessed comorbidities and pharmacologic treatment. Methods: National Patient Register data were used to estimate the overall prevalence of adults (≥18 years) with a registered ADHD diagnosis from 2006 to 2011, and the incidence of newly registered diagnoses from 2007 to 2011. Data from the Prescribed Drug Register were used to estimate the mean dose of the most frequently prescribed ADHD medication. Results: The estimated annual prevalence (N=44,364) of diagnosed ADHD increased from 0.58 per 1,000 persons in 2006 to 3.54 per 1,000 persons in 2011. The estimated annual incidence of newly diagnosed ADHD (N=24,921) increased from 0.39 per 1,000 persons to 0.90 per 1,000 persons between 2007 and 2011. At least one comorbidity was diagnosed in 52.6% of adults with ADHD (54.0% of newly diagnosed adults), with anxiety, substance use disorders, and depression being the most common. Among all adults with ADHD, 78.9% (65.7% of newly diagnosed adults) were prescribed ADHD medication and one-third were prescribed more than one add-on medication. Osmotic release oral system methylphenidate was the most commonly used medication. The mean daily dose was 51.5 mg, and was significantly higher in males, patients with substance use disorders, patients with drug holidays, and patients with at least one add-on medication. The most frequent concomitant medications were anxiolytics and hypnotics. Conclusion: In Sweden, the number of adults diagnosed with ADHD increased between 2006 and 2011, and the majority of patients were prescribed ADHD-specific medication. Over one-half of patients had psychiatric comorbidities; one-third were prescribed more than one add-on medication. Consumption of pharmacologic ADHD medication was high in specific patient subpopulations. Keywords: prevalence, attention-deficit/hyperactivity disorder, adult, register analysis, daily dose, methylphenidate, comorbidity, concomitant medication, treatment dosingPolyzoi MAhnemark EMedin EGinsberg YDove Medical Pressarticleprevalence – attention-deficit/hyperactivity disorder – adult – register analysis – daily dose – methylphenidateNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 1149-1161 (2018)
institution DOAJ
collection DOAJ
language EN
topic prevalence – attention-deficit/hyperactivity disorder – adult – register analysis – daily dose – methylphenidate
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle prevalence – attention-deficit/hyperactivity disorder – adult – register analysis – daily dose – methylphenidate
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Polyzoi M
Ahnemark E
Medin E
Ginsberg Y
Estimated prevalence and incidence of diagnosed ADHD and health care utilization in adults in Sweden – a longitudinal population-based register study
description Maria Polyzoi,1 Ewa Ahnemark,2 Emma Medin,1,3 Ylva Ginsberg4,5 1PAREXEL International, Stockholm, Sweden; 2Medical Affairs Department, Shire Sweden AB, Stockholm, Sweden; 3Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden; 4Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 5Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Institutet, Stockholm, Sweden Background: Although the worldwide prevalence of attention-deficit/hyperactivity disorder (ADHD) in adults is estimated to be between 2% and 5%, it is considered to be underdiagnosed. This register study explored the prevalence of diagnosed ADHD and incidence of newly diagnosed ADHD in Swedish adults over time, and assessed comorbidities and pharmacologic treatment. Methods: National Patient Register data were used to estimate the overall prevalence of adults (≥18 years) with a registered ADHD diagnosis from 2006 to 2011, and the incidence of newly registered diagnoses from 2007 to 2011. Data from the Prescribed Drug Register were used to estimate the mean dose of the most frequently prescribed ADHD medication. Results: The estimated annual prevalence (N=44,364) of diagnosed ADHD increased from 0.58 per 1,000 persons in 2006 to 3.54 per 1,000 persons in 2011. The estimated annual incidence of newly diagnosed ADHD (N=24,921) increased from 0.39 per 1,000 persons to 0.90 per 1,000 persons between 2007 and 2011. At least one comorbidity was diagnosed in 52.6% of adults with ADHD (54.0% of newly diagnosed adults), with anxiety, substance use disorders, and depression being the most common. Among all adults with ADHD, 78.9% (65.7% of newly diagnosed adults) were prescribed ADHD medication and one-third were prescribed more than one add-on medication. Osmotic release oral system methylphenidate was the most commonly used medication. The mean daily dose was 51.5 mg, and was significantly higher in males, patients with substance use disorders, patients with drug holidays, and patients with at least one add-on medication. The most frequent concomitant medications were anxiolytics and hypnotics. Conclusion: In Sweden, the number of adults diagnosed with ADHD increased between 2006 and 2011, and the majority of patients were prescribed ADHD-specific medication. Over one-half of patients had psychiatric comorbidities; one-third were prescribed more than one add-on medication. Consumption of pharmacologic ADHD medication was high in specific patient subpopulations. Keywords: prevalence, attention-deficit/hyperactivity disorder, adult, register analysis, daily dose, methylphenidate, comorbidity, concomitant medication, treatment dosing
format article
author Polyzoi M
Ahnemark E
Medin E
Ginsberg Y
author_facet Polyzoi M
Ahnemark E
Medin E
Ginsberg Y
author_sort Polyzoi M
title Estimated prevalence and incidence of diagnosed ADHD and health care utilization in adults in Sweden – a longitudinal population-based register study
title_short Estimated prevalence and incidence of diagnosed ADHD and health care utilization in adults in Sweden – a longitudinal population-based register study
title_full Estimated prevalence and incidence of diagnosed ADHD and health care utilization in adults in Sweden – a longitudinal population-based register study
title_fullStr Estimated prevalence and incidence of diagnosed ADHD and health care utilization in adults in Sweden – a longitudinal population-based register study
title_full_unstemmed Estimated prevalence and incidence of diagnosed ADHD and health care utilization in adults in Sweden – a longitudinal population-based register study
title_sort estimated prevalence and incidence of diagnosed adhd and health care utilization in adults in sweden – a longitudinal population-based register study
publisher Dove Medical Press
publishDate 2018
url https://doaj.org/article/18f9face43844ec0bb8caa0db8669008
work_keys_str_mv AT polyzoim estimatedprevalenceandincidenceofdiagnosedadhdandhealthcareutilizationinadultsinswedenndashalongitudinalpopulationbasedregisterstudy
AT ahnemarke estimatedprevalenceandincidenceofdiagnosedadhdandhealthcareutilizationinadultsinswedenndashalongitudinalpopulationbasedregisterstudy
AT medine estimatedprevalenceandincidenceofdiagnosedadhdandhealthcareutilizationinadultsinswedenndashalongitudinalpopulationbasedregisterstudy
AT ginsbergy estimatedprevalenceandincidenceofdiagnosedadhdandhealthcareutilizationinadultsinswedenndashalongitudinalpopulationbasedregisterstudy
_version_ 1718401966190624768

Ejemplares similares